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Antipsychotic drugs are widely used in treating schizophrenia, bipolar disorder, and other
psychiatric disorders. Many of these drugs, despite their therapeutic advantages, substan-
tially increase body weight.We assessed the association of alleles of 31 genes implicated
in body weight regulation with weight gain among patients being treated with speciﬁc
antipsychotic medications in the clinical antipsychotic trials in intervention effectiveness
study, we found that rs2237988 in Potassium Channel Inwardly Rectifying Subfamily J
Member 11 (KCNJ11), rs13269119 in Solute carrier family 30 member 8 (SLC30A8 ), and
rs9922047 in fat mass and obesity associated (FTO) were associated with percent weight
gain.We also observed the signiﬁcant interaction of rs11643744 by treatment effect on the
weight gain.
Keywords: antipsychotic drugs, weight gain, schizophrenia, CATIE Study, candidate genes, energy homeostasis,
KCNJ11 gene, FTO gene
INTRODUCTION
Antipsychotic drugs (APDs) are effective treatments for sev-
eral common psychiatric conditions, including schizophrenia and
bipolar disorder. There has been a dramatic increase in the use
of APDs in recent years. Some but not all APDs are associ-
ated with weight gain and metabolic dysregulation, a concern
because many individuals with psychotic disorders are already
metabolically vulnerable (Allison et al., 1999; Allison and Casey,
2001; Cope et al., 2005; Brecher et al., 2007; Strassnig et al.,
2007; Correll et al., 2009; Varley and McClellan, 2009). Though
possessing many advantages, many APDs have a major liability
by virtue of their ability to promote substantiated weight gain
and metabolic dysregulation in an already metabolically vulnera-
ble population. During the past decade there have considerable
research efforts to quantify, understand, prevent, and alleviate
these adverse effects. Also, the marked increase in the use of these
drugs, the importance of the mental illnesses they are used to treat,
their profound effects on weight and metabolic functioning, and
the known harms of obesity, diabetes, and metabolic dysregula-
tion all underscore the importance of continued research in this
area.
Even among patients taking any single APD, there is great vari-
ability in the amount of weight gainedwhile taking the drug. These
inter-individual differences could be due to genetic differences in
the genes encoding the molecular targets for the drug in question
and/or the genes encodingmolecules affecting the pharmacokinet-
ics of the drug (Cope et al., 2005). Although several investigators
have examined genetic predictors of weight gain among persons
taking APDs, few have tested for genetic mediators of weight gain
response per se, or have examined a large number of candidate
genes in large number of subjects (Need et al., 2009). In this study,
therefore, we aimed to examine in the clinical antipsychotic trials
in intervention effectiveness (CATIE) study by testing for genetic
association of weight gain with single nucleotide polymorphisms
(SNPs) in genes involved in body weight regulation.
MATERIALS AND METHODS
GENE SELECTION AND STUDY DATA
We related 31 obesity-related genes to the effects of ﬁveAPDs (per-
phenazine, olanzapine, quetiapine, risperidone, and ziprasidone)
on the weight gain in 732 participants with genotypic data (out
of 774 participants receiving treatment with at least one of these
drugs) of the total 1493 subjects in CATIE study. The baseline
antipsychotic medication at the time of randomization and other
descriptive analysis such as distribution of age, sex, race, and base-
line weight is given in Table 1. The CATIE study was conducted
between January 2001 and December 2004 at 57 clinical sites in
the United States, ascertaining individuals who were 18–65 years
of age, had the DSM-IV diagnosis of schizophrenia, and were
able to take appropriate oral medications. Patients were randomly
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Table 1 | Baseline covariates and antipsychotic drug history of patients with available genotypic data prior to randomization.
Olanzapine
(2nd generation;
N =167)
Perphenazine
(1st generation;
N =138)
Quetiapine
(2nd generation;
N =164)
Risperidone
(2nd generation;
N =169)
Ziprasidone
(2nd generation;
N =94)
Total (N =732)
AGE –YEAR (MEAN±SD)
Age 40.94±11.17 40.81±10.61 41.38±11.21 40.99±11.10 40.44±11.16 40.96±11.03
BASELINEWEIGHT – LBS (MEAN±SD)
Baseline weight 195.09±46.12 193.87±50.24 197.62±45.51 197.94±51.00 192.44±41.37 195.74±47.30
SEX – NUMBER (%)
Male 123 (74) 102 (74) 123 (75) 125 (74) 66 (70) 539 (74)
Female 44 (26) 36 (26) 41 (25) 44 (26) 28 (30) 193 (26)
RACE – NUMBER (%)
White 110 (66) 88 (64) 117 (71) 112 (66) 56 (60) 483 (66)
Black 53 (32) 43 (31) 43 (26) 49 (29) 31 (33) 219 (30)
Other 4 (3) 7 (5) 4 (2) 8 (5) 7 (7) 30 (4)
BASELINEANTIPSYCHOTIC MEDICATION – NUMBER (%)
1st Generation 17 (10) 10 (7) 16 (10) 19 (11) 12 (13) 74 (10)
2nd Generation 78 (47) 55 (40) 77 (47) 74 (44) 38 (40) 322 (44)
1st and 2nd Generation 5 (3) 6 (4) 6 (4) 9 (5) 4 (4) 30 (4)
None 67 (40) 67 (49) 65 (40) 67 (40) 40 (43) 306 (42)
assigned to oral olanzapine, perphenazine, quetiapine, risperidone
under double-blinded treatment conditions in Phase 1, and fol-
lowed for up to 18months or until treatment was discontinued
for any reason. Ziprasidone was added to the study in 2002. Infor-
mation on the prior antipsychotic medications names and their
generation are given in Table S1A in Supplementary Material and
number of individuals randomized to a particular antipsychotic
drug at base line is given in Table S1B in Supplementary Material.
Note that the information provided in Tables S1A,B in Supple-
mentary Material is restricted to individuals included for further
genetic analysis.
In addition to the primary psychiatric outcomes, patients were
also monitored for metabolic effects of the drugs, including pulse,
blood pressure, and body weight to evaluate the effect of antipsy-
chotic treatments on weight gain, glucose and lipid metabolism,
waist–hip ratio (WHR), and body mass index (BMI; Stroup et al.,
2003 and Lieberman et al., 2005).
We investigated total weight gain in lbs within the duration
of the study, weight gain per month of treatment, and weight
gain> 7% in732 individuals. The results are shown in theTable 2A
(without any covariate adjustment) and Table 2B with covari-
ates such as age, age squared, sex, race, baseline weight (only
included for weight gain outcome variable), and treatment (olan-
zapine, quetiapine, risperidone, ziprasidone, and perphenazine).
Our results given in Table 2A were similar to the results given
in Table 3 of original study by Lieberman et al. (2005). Note
that Lieberman et al. (2005) did not adjust for covariates in their
analysis of weight measures.
Genome-wide association analysis (GWAS) of the CATIE data
was conducted by Perlegen Sciences by using the Affymetrix 500K
gene chip on 774 cases. Only 732 individuals had both clinical and
genetic data available. The 1084 SNPs spanning the 31 selected can-
didate genes were used to perform the post hoc association analysis
for effects of gene-by-drug interactions on weight gain during
the course of treatment. Genes related to body weight regulation
were selected, in part, because of their roles in the neural systems
affected by psychotropic agents and included (Chung and Leibel,
2008; Lindgren and McCarthy, 2008; van Vliet-Ostaptchouk et
al., 2009; Walley et al., 2009). These included the dopamine
receptors DRD2 and DRD4; Serotonin Transporter (SLC6A4), 5-
HydroxytryptamineReceptors (HTR1A,HTR2A,HTR2C,HTR1F,
and HTR6); adrenergic receptors (ADRA1A, ADRA2A, ADRB3);
Histamine receptors 1 and 2 (HRH1, HRH2); Cholinergic recep-
tor, muscarinic 3 (CHRM3); synaptosomal associated protein
SNAP25; genes associated with obesity including Leptin (LEP),
Leptin receptor (LEPR), and fat mass and obesity associated
(FTO); and genes associated with type 2 diabetes including per-
oxisome proliferator activated receptor gamma (PPARG); Tran-
scription Factor 7 Like 2 (TCF7L2), Potassium Channel Inwardly
Rectifying Subfamily J Member 11(KCNJ11), hematopoietically
expressed homeobox (HHEX), Insulin likeGrowth Factor Binding
Protein 2 (IGF2BP2),CDK5Regulator Subunit-AssociatedProtein
1-Like (CDKAL1), Solute carrier family 30 member 8 (SLC30A8),
Cyclin Dependent Kinase Inhibitors 2A and 2B (CDKN2A and
CDKN2B), and Insulin degrading enzyme (IDE). We included
intragenic SNPs and SNPs within or 50 kb 5′ or 3′ of these candi-
date genes. The list of all genes included in the study and number
of SNPs within and ﬂanking the genes are provided in Table S2 in
Supplementary Material.
Body weight was measured at baseline and then repeatedly at
the post-randomization visits. The timing of the visits varied by
patient; hence, we did not have gain-in-weight measurements for
all individuals at speciﬁc intervals following the start of treat-
ment. With antipsychotics, the majority of weight gain (but by no
means all) generally occurs by 120 days (Wetterling, 2001; Gen-
tile, 2006; Gebhardt et al., 2009). This observation, coupled with
the fact that we had considerable data around that time point,
led to our choice of 120 days in the model. Hence, we predicted
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Table 2A |Weight measures without adjusting for covariates.
Olanzapine Quetiapine Risperidone Perphenazine Ziprasidone
Total weight gain (SE) 9.90 (1.31) 2.01 (1.32) 1.08 (1.53) −1.57 (1.55) −2.05 (1.80)
Weight gain/month (SE) 1.82 (0.33) 0.73 (0.35) 0.47 (0.26) 0.02 (0.26) −0.55 (0.54)
Percent weight gain (SE) 4.64 (0.62) 0.68 (0.67) 0.30 (0.72) −0.69 (0.79) −1.97 (0.79)
Weight gain>7% – no./total no. (%) 45/167 (27) 23/164 (14) 25/169 (15) 16/138 (12) 6/94 (6)
Table 2B |Weight measures after adjusting for covariates.
Olanzapine Quetiapine Risperidone Perphenazine Ziprasidone
Total weight gain (SE) 9.76 (1.27) 2.24 (1.30) 1.07 (1.52) −1.41 (1.55) −2.43 (1.78)
Weight gain/month (SE) 1.70 (0.32) 0.96 (0.37) 0.41 (0.24) 0.05 (0.27) −0.97 (0.52)
Percent weight gain (SE) 5.56 (0.69) 1.61 (0.73) 1.12 (0.68) 0.23 (0.79) −1.51 (0.86)
Weight gain>7% – no./total no. (%) 49/167 (29) 29/164 (18) 28/169 (17) 19/138 (14) 7/94 (7)
Table 3A |Weight measures without adjusting for covariates (Model 1: weight gain was estimated using combined data for all treatments).
Olanzapine Quetiapine Risperidone Perphenazine Ziprasidone
Weight gain at 120th day (SE) 5.05 (0.60) 2.55 (0.60) 2.81 (0.52) 1.05 (0.68) 0.84 (0.80)
Percent weight gain at 120th day (SE) 2.75 (0.31) 1.46 (0.30) 1.58 (0.27) 0.77 (0.34) 0.47 (0.41)
Weight gain>7% — no./total no. (%) 22/167 (13) 13/164 (8) 11/169 (7) 11/138 (8) 3/94 (3)
Table 3B |Weight measures after adjusting for covariates (Model 1: weight gain was estimated using combined data for all treatments).
Olanzapine Quetiapine Risperidone Perphenazine Ziprasidone
Weight gain at 120th day (SE) 4.98 (0.58) 2.60 (0.59) 2.82 (0.51) 1.07 (0.68) 0.80 (0.79)
Percent weight gain at 120th day (SE) 2.73 (0.31) 1.48 (0.30) 1.58 (0.27) 0.79 (0.34) 0.46 (0.40)
Weight gain>7% – no./total no. (%) 22/167 (13) 13/164 (8) 8/169 (5) 11/138 (8) 3/94 (3)
weight gain for each subject at the 120th day with a mixed model
using weights measured at given time points as outcome, and both
drug treatment duration and the square-root of drug treatment
duration after randomization as predictors. We derived the pre-
diction equation for weight gain at the 120th day by two ways,
namely, Model 1 predicted weight gain estimated using com-
bined data with all treatments as a non-linear function of time
points only as described above; and Model 2 predicted weight gain
estimated separately for each treatment as a non-linear function
of time points and randomized treatment (i.e., we derived the
ﬁve prediction equations for weight gain for each treatment by
stratiﬁed sample with respect to treatments olanzapine, quetiap-
ine, risperidone, perphenazine, and ziprasidone). Model 1 results
are depicted in Tables 3A,B with and without covariate adjust-
ments, respectively. Similarly, we estimated weight gain, percent
weight gain, and weight gain> 7% at 120th day, using model
2 and the results are depicted in Tables 4A,B without adjust-
ment of covariates and with adjustment of covariates, respectively.
Note that model 1 weight gain predictions were underestimating
compared to other studies (Allison et al., 1999; Wirshing et al.,
1999; Sicard et al., 2010; Cuerda et al., 2011; and Citrome et al.,
2011), speciﬁcally for olanzapine-induced weight gain in schizo-
phrenic patients. However, model 2 weight gain predictions were
consistent with other studies. Both outcome variables, namely,
weight gain and percent weight gain were checked for normality,
and observations beyond four SD were considered to be outliers
and were omitted from further analysis in the generalized lin-
ear model (GLM). However, we observed that both the analyses
including outliers and the analyses excluding outliers gave similar
results.
We tested Hardy–Weinberg equilibrium (HWE) at each locus
by using the chi-square with 1 degree of freedom (df) test (Weir,
1996). SNPs on the X chromosome were tested for HWE test by
using data from females only. We also computed linkage dise-
quilibrium (LD) among markers in the same gene by using r2
values. We tested the effect of each of 1084 SNPs on weight
gain and percent weight gain at the 120th day by using a GLM
framework.
We modeled age, age squared, sex, race, baseline weight
(only included for weight gain outcome variable), and treat-
ment (olanzapine, quetiapine, risperidone, ziprasidone, and per-
phenazine) as covariates in the linear model in addition to additive
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Table 4A |Weight measures without adjusting for covariates (Model 2: weight gain was estimated separately for each treatment).
Olanzapine Quetiapine Risperidone Perphenazine Ziprasidone
Weight gain at 120th day (SE) 6.96 (0.61) 2.43 (0.59) 2.83 (0.50) −0.10 (0.68) −1.05 (0.80)
Percent weight gain at 120th day (SE) 3.71 (0.32) 1.38 (0.30) 1.59 (0.26) 0.39 (0.37) −0.57 (0.41)
Weight gain>7% – no./total no. (%) 30/167 (18) 13/164 (8) 11/169 (7) 9/138 (7) 3/94 (3)
Table 4B |Weight measures after adjusting for covariates (Model 2: weight gain was estimated separately for each treatment).
Olanzapine Quetiapine Risperidone Perphenazine Ziprasidone
Weight gain at 120th day (SE) 6.83 (0.59) 2.47 (0.58) 2.85 (0.49) −0.05 (0.68) −1.02 (0.78)
Percent weight gain at 120th day (SE) 3.66 (0.31) 1.40 (0.30) 1.59 (0.26) 0.40 (0.36) −0.55 (0.40)
Weight gain>7% – no./total no. (%) 32/167 (19) 11/164 (7) 8/169 (5) 8/138 (6) 3/94 (3)
and dominance effects of the SNP. However, almost all of the
individuals were off the prior drugs within 3months after ran-
domization. To control for extraneous variance due to antipsy-
chotic drug history before randomization, and continual use of
drugs (a cross-titration period) in addition to treatment drugs
after randomization, we created a variable called “highest gen-
eration drug.” The highest generation drug was deﬁned as the
maximum of ﬁrst and/or second generation drugs used before
randomization to treatment drugs. We included two interaction
terms in the linear model to control for extraneous variance due
to prior drug use and are described as follows. The ﬁrst interaction
term in the linear model included highest generation drug used
before randomization by its duration (i.e., how long the individ-
ual was on the highest generation drug before randomization). In
cases in which the participant was taking multiple drugs of the
same generation, we chose the drug with the longest duration of
administration. Similarly, to control for extraneous variance due
to some participants’ continual use of prior drugs in addition to
randomized treatment drug in the titration period, we included
the second interaction term in the model involving highest gener-
ation drug among prior drugs by its duration. Similar models were
used for quantile regression (Redden et al., 2004) by using data at
the 10th and 90th quantiles of the respective variables. Note that
using these covariates will control for extraneous variance and will
have very little effect on our association testing of primary out-
come and SNPs. Multiple test correction for association testing
was performed using a method proposed be Gao et al. (2008) for
correlated SNPs within genes.
RESULTS
Five treatment drugs were randomly assigned to the patients in the
study: olanzapine, quetiapine, risperidone, ziprasidone, and per-
phenazine. After adjustment for covariates, treatment drug had
a signiﬁcant effect on percent weight gain (p-values< 0.0001).
In a pair-wise comparison of each treatment drug, ziprasidone
was used as a reference because it has been found to produce
the lowest weight gain compared with the other drugs in this
study (Allison et al., 1999; Brecher et al., 2007; Strassnig et al.,
2007). Olanzapine had a signiﬁcant effect on both weight gain
and percent weight gain after Scheffe correction for multiple
pair-wise comparisons (p-values< 0.0001). Means and SEs are in
Tables 2–4. Tables 5A,B contain the signiﬁcant p-values for main
effects of SNPs and also SNP x Treatment interaction effects
in genes FTO, KCNJ11, CDKL1, and SLC30A, using a GLM
and a quantile regression method corresponding to phenotypes
estimated using combined treatment groups (Model 1) and
separately within each treatment group (Model 2), respec-
tively. We included only FTO, KCNJ11, CDKL1, and SLC30A
in Tables 5A,B because the ﬁve SNPs (rs11643744 in FTO
(model 1 p-value= 0.024 and model 2 p-value= 0.02), rs9922047
in FTO (model 1 p-value= 0.002 and model 2 p-value= 0.05),
and rs2237988 in KCNJ11 (model 1 p-value= 0.013), rs4712595
in CDKL1 (model 2 p-value= 0.03 and marginally signiﬁcant
(p = 0.051) for model 1, and rs13269119 in SLC30A8 (model 2
p-value= 0.04)) in these genes were found to be signiﬁcant after a
multiple tests correction. HWE test results and association results
for all 1084 SNPs are provided in Tables S3A,B in Supplementary
Material for weight gain when weight gain was estimated using all
treatment groups together (model 1) and in Tables S4A,B in Sup-
plementary Material for percent weight gain when weight gain was
estimated separately within each treatment group (model 2). In
the SNP association analysis using quantile regression at the 10th
percentile, SNP rs2237988 5′ of KCNJ11 in an intron of ABCC8
(which encodes the Sulfonylurea Receptor) showed a signiﬁcant
association with percent weight gain even after multiple tests cor-
rection for multiple testing (Multiple tests corrected p-value 0.013,
Table 5A for model 1). However, the signiﬁcant association was
not observed with percent weight gain when similar analysis was
performed using estimated percent weight gain separately within
each treatment group (p = 3.78× 10−4 and multiple tests cor-
rected p-value 0.30 in Table 5B). We further analyzed rs2237988
with adjustments for diabetes status since KCNJ11 and ABCC8
have been causally implicated in diabetes mellitus (Florez et al.,
2003). Results are shown in Tables 6A,B for model 1 (phenotype
estimated using combined treatment groups) and model 2 (phe-
notype estimated using separately within each treatment group),
respectively. We found that rs2237988 showed signiﬁcant asso-
ciations with percent weight gain when these parameters were
adjusted for serum glucose concentration [p = 2.6× 10−6 (mul-
tiple test corrected p-value= 0.003) in Table 6A] using model 1.
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Also, percent weight gain association with rs2237988 was signif-
icant after adjusting for serum glucose concentration in model
2 (p = 4.67× 10−5 and multiple tests corrected p-value 0.04 in
Table 6B). The SNPs rs4712595 of CDKL1 and rs13269119 of
SLC30A8 showed signiﬁcant associations with percent weight gain
even after stringent multiple tests correction for multiple test-
ing in the analysis of 10th percentile, when percent weight was
analyzed using estimated percent weight gain separately within
each treatment group (multiple tests corrected p-value 0.03 and
0.04, respectively, see Table 5B). Since both genes CDKL1 and
SLC30A8 have been implicated in diabetes mellitus, we further
analyzed rs4712595 and rs13269119 adjusting for diabetes status
(seeResults inTables 6C,D).Only association between rs13269119
of SLC30A8 and percent weight gain remain signiﬁcant after
adjusting of glucose (p = 5.08× 10−5, and p = 0.04 with multiple
tests correction).
The SNP rs9922047 in FTO (a non-coding SNP in intron 1)
was signiﬁcantly associated with percent weight gain in the
quantile regression at the 10th percentile using model 1 (mul-
tiple tests corrected p-value= 0.002) and also in model 2 (mul-
tiple tests corrected p-value= 0.05). An interaction between
rs11643744 (another non-coding SNP in intron 1) in the FTO
and treatment drug for weight gain was found to be signiﬁ-
cant after multiple tests correction in both models 1 (multiple
tests corrected p-value= 0.024) and 2 (multiple tests corrected
p-value= 0.02).
The adjustedmean values and SEs of weight gain for each geno-
type at rs2237988 (KCNJ11), rs4712595 (CDKAL1), rs13269119
(SLC30A8), rs9922047 (FTO) are shown in Tables 7A–D, respec-
tively. The adjusted mean values and SEs from the quantile
regression model for the treatment drug-by-genotype interaction
effect at rs11643744 in FTO gene are shown in Table 8. We also
investigated whether signiﬁcant associations of KCNJ11,CDKAL1,
SLC30A8, FTO SNPs with drug-related weight gain might be due
to antecedent predisposition to adiposity, as reﬂected in base-
line body weight. The association p-values of SNPs with baseline
weight and BMI in all candidate genes are given in Tables S5A,B
in Supplementary Material. There was no signiﬁcant association
detected for any candidate gene – including KCNJ11, CDKAL1,
SLC30A8, FTO – with the baseline weight or BMI.
DISCUSSION
We performed genetic analysis on predicted induced weight gain
and percent weight gain at the 120th day in schizophrenic patients
from CATIE study. The analyses were performed on outcome
variable estimated using two ways, namely, predicted weight gain
estimated using combined data with all treatments (model 1);
and predicted weight gain estimated separately for each treatment
(model 2). We found a signiﬁcant association of rs2237988 in the
KCNJ11 gene with percent weight gain estimated using combined
data with all treatments. KCNJ11 encodes an ATP-sensitive potas-
sium channel, Kir6.2, – that interacts with the SUR1 (ABCC8)
subunit to determine insulin release (Inagaki et al., 1995). Both
ABCC8 and KCNJ11 have been causally implicated in rare
forms of diabetes, and ATP-sensitive potassium channels medi-
ate some aspects of hypothalamic function related to food intake
(Spanswick et al., 1997). In several studies type 2 diabetes
prevalence among persons with schizophrenia has been found to
be higher than in the general population (Lean and Pajonk, 2003;
Gough and O’Donovan, 2005; Holt and Peveler, 2006; Allison et
al., 2009). Also, the risk of diabetes in schizophrenia is increased
by use of atypical APDs (Lean and Pajonk, 2003). The Consen-
sus Statement, issued in 2004, indicated that drug-induced insulin
resistance may occur because of weight gain or change in body
fat distribution, or by direct effects on insulin-sensitivity target
tissues (American Diabetes Association et al., 2004). We therefore
further analyzed the genotypic data in KCNJ11 for association
with percent weight gain with adjustment for baseline diabetes
status (presence or absence), and serum glucose concentration
at the 120th day after randomization. The serum glucose con-
centration was estimated for each subject at the 120th day with
a mixed model by using the serum glucose concentration mea-
sured at given time points as the outcome. The association of
rs2237988 in KCNJ11 with percent weight gain remained signif-
icant after multiple tests correction and with adjustment for the
serum glucose concentration (p = 0.003). However, the signiﬁcant
association between rs2237988 and percent weight gain was not
signiﬁcant when using estimated percent weight gain separately
within each treatment group. We also observed signiﬁcant associ-
ations of rs4712595 of CDKL1 gene and rs13269119 of SLC30A8
with percent weight gain estimated at 120th day separately within
each treatment. Both CDKL1 gene and SLC30A8 have been impli-
cated for Type 2 diabetes. Thus, we further analyzed the geno-
typic data with percent weight gain with adjustment for baseline
diabetes status (presence or absence), and serum glucose concen-
tration at the 120th day after randomization. The association of
rs13269119 in SLC30A8 with percent weight gain remained signif-
icant after multiple tests correction and with adjustment for the
serum glucose concentration (p = 0.04). We found that rs4712595
of CDKAL1 association disappeared after correction for diabetes
status; implying weight gain may be mediated by type 2 diabetes
in the presence of rs4712595 in Schizophrenic patients. Genetic
intervals containing SLC30A8 (8q24.11) and CDKL1 (6p22.3)
have both been repeatedly implicated in type 2 diabetes (T2D)
by association analyses (Lyssenko et al., 2008; McCarthy, 2010).
SLC30A8 (solute carrier family 30 (zinc transporter), member 8)
mediates zinc transport, speciﬁcally in beta cells. The gene is co-
expressed in insulin-producing cells (Chimienti et al., 2004) where
zinc participates in the processing of proinsulin to insulin and the
release of insulin in response to glucose (Kirchhoff et al., 2008).
CDKL1 (cdk5 regulatory subunit-associated protein 1-like 1) is
associated with T2D and low birthweight, the latter possibly con-
tributing to the risk of diabetes. In individuals in whom T2D is
associated with allelic variation in CDKL1, T2D is not contingent
upon obesity, as it is for many other diabetes-associated genes. The
molecular physiology of this protein is not well understood, but
it may play a role in proinsulin processing and/or mitochondr-
ial oxidative metabolism related to beta cell release of insulin in
response to glucose (Steinthorsdottir et al., 2007; Kirchhoff et al.,
2008; Ohara-Imaizumi et al., 2010). Atypical antipsychotic med-
ications may adversely affect beta cell function directly (Ader et al.,
2005) – rendering allelic variation in genes such as SLC30 A8 and
CDKL1 possible mediators of individual susceptibility to T2D as
a consequence of exposure to these drugs. Increased circulating
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insulin, or alterations of the timing and magnitude of endoge-
nous release, may cause of increased body weight by effects on
food intake (Mäkimattila et al., 1999), and might account for the
association with weight gain detected here.
Fat mass and obesity associated has been associated with adi-
posity in several large genome-wide association studies (Dina et al.,
2007; Frayling et al., 2007; Scuteri et al., 2007). The FTO SNP,
rs9939609, which was previously associated with obesity, was not
Table 7A | Adjusted mean percent weight gain corresponding to
genotypes at rs2237988 (KCNJ11), using model 2.
Genotype Mean SE N
C/C 1.479 0.189 490
C/T 1.801 0.291 205
T/T 3.017 0.405 36
Table 7B | Adjusted mean percent weight gain corresponding to
genotypes at rs4712595 (CDKAL1), using model 2.
Genotype Mean SE N
C/C 1.66 0.28 201
C/T 1.80 0.24 328
T/T 1.26 0.28 194
Table 7C | Adjusted mean percent weight gain corresponding to
genotypes at rs13269119 (SLC30A8 ), using model 2.
Genotype Mean SE N
C/C 1.40 0.17 586
C/G 2.48 0.37 130
G/G 4.09 1.33 15
Table 7D | Adjusted mean percent weight gain corresponding to
genotypes at rs9922047 (FTO), using model 2.
Genotype Mean SE N
C/C 1.56 0.34 133
C/G 1.81 0.21 357
G/G 1.45 0.29 237
associated with weight gain in our study. Recently, Perez-Iglesias
et al. (2010) investigated the association of FTO rs9939609 with
weight gain in the context of treatment with haloperidol, Olan-
zapine, risperidone, ziprasidone, aripiprazole, or quetiapine. After
1 year of treatment with APDs, there was no signiﬁcant effect on
weight gain of the 3 genotypes deﬁned by the rs9939609 variant.
However, the two SNPs associated with weight gain in CATIE,
rs9922047, and rs11643744 are within 10 kb, and 20 kb respec-
tively, of rs9939609 and are in LD with rs9939609. Note that LD
varies among populations and estimation of LD depends on the
sample size. Therefore, it is possible that Perez-Iglesias et al. (2010)
did not observed any association with rs9939609 due to difference
between genetic make-up of the studies (Spanish sample in Perez-
Iglesias and European American sample in our study) and small
sample size (n = 143 in Perez-Iglesias and n = 732 in our study).
FTO encodes a putative non-heme dioxygenase, but it is unclear
how genetic variation at the FTO locus leads to increased adiposity
(Han et al., 2010). The association may be conveyed – in part –
by effects related to a nearby gene, RPGRP1L, that is a component
of the ciliary basal body, an organelle implicated in the obesity
of individuals with Bardet–Biedl syndrome (Stratigopoulos et al.,
2008, 2011).
The genes implicated in this analysis play a role in energy
homeostasis, presumably by hypothalamic mechanisms. These
genes have also been implicated in aspects of glucose/insulin
homeostasis. We endeavored to control for the latter because we
were focused more on body weight effects, and the subjects were
not fully phenotyped regarding diabetes. However, some antipsy-
chotics have been implicated having direct adverse consequences
for beta cell function (Best et al., 2005). The genes that we iden-
tiﬁed here may mediate effects on both body weight and diabetes
susceptibility.
ACKNOWLEDGMENTS
This research was supported in part by NIH grant R01DK52431-
16, and New York Obesity Research Center Grant P30 DK26687-
25. We also thank Mihir Limdi, a summer intern in the Section
on Statistical Genetics, Department of Biostatistics at UAB for his
help in preparing the manuscript.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at http://www.frontiersin.org/pharmacogenetics_and_
pharmacogenomics/10.3389/fgene.2011.00056/abstract
Table 8 | Adjusted mean weight gain in lbs for treatment and genotypes at rs11643744 (FTO gene) in the interaction analyses.
Treatment drug A/A A/G G/G
Mean SE N Mean SE N Mean SE N
Olanzapine 4.44 0.77 94 −0.53 1.01 56 2.00 1.63 17
Perphenazine* 2.20 0.84 86 2.70 0.87 43 2.86 3.26 9
Quetiapine 4.14 0.94 80 1.48 0.83 74 4.57 1.56 10
Risperidone 2.71 0.84 85 3.16 0.83 63 1.24 1.52 20
Ziprasidone 3.11 1.17 52 2.31 1.41 35 3.23 1.58 6
*Except Perphenazine, which is ﬁrst generation antipsychotic drug, all treatment drugs in table are second generation antipsychotic drug.
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